Abstract Body

Background: Hepatitis C therapy is living its revolution. Several new anti-hepatitis C virus (HCV) drugs have reached the market and many others, including direct-acting antivirals (DAAs) and host-targeted agents (HTAs), are at the late clinical developmental stage. Several all-oral, interferon-free drug combination strategies are being developed, including nucleotide-based strategies, nucleoside-free strategies based on 3 DAAs with a low barrier to resistance, nucleoside-free strategies based on 2 DAAs including at least one second-generation drug with a higher barrier to resistance. Infection cure rates over 90% can be expected with these new therapies. Conclusions: A number of unanswered questions and challenges however remain that will need to be addressed, including treatment of special populations, the role of ribavirin in interferon-free regimens, the role of HCV resistance in HCV treatment failures, strategic choices and cost issues, as well as screening and broad access to care in resource-constrained areas.